These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer. Kobayashi S; Tomokuni A; Gotoh K; Takahashi H; Akita H; Marubashi S; Yamada T; Teshima T; Nishiyama K; Yano M; Ohigashi H; Ishikawa O; Sakon M Cancer Chemother Pharmacol; 2015 Dec; 76(6):1191-8. PubMed ID: 26547917 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Lin LL; Picus J; Drebin JA; Linehan DC; Solis J; Strasberg SM; Tan B; Thorstad WL; Myerson R Am J Clin Oncol; 2005 Jun; 28(3):234-41. PubMed ID: 15923794 [TBL] [Abstract][Full Text] [Related]
6. Phase I trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study). Katayose Y; Rikiyama T; Motoi F; Yamamoto K; Yoshida H; Morikawa T; Hayashi H; Kanno A; Hirota M; Satoh K; Ariga H; Suzuki M; Ohyauchi M; Kondo Y; Ikeya S; Ogawa Y; Shimosegawa T; Egawa S; Unno M Hepatogastroenterology; 2011; 58(112):1866-72. PubMed ID: 22234055 [TBL] [Abstract][Full Text] [Related]
7. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. Lee KJ; Yi SW; Cha J; Seong J; Bang S; Song SY; Kim HM; Park SW Cancer Chemother Pharmacol; 2016 Oct; 78(4):841-6. PubMed ID: 27586966 [TBL] [Abstract][Full Text] [Related]
8. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW J Hepatol; 2020 Nov; 73(5):1109-1117. PubMed ID: 32446715 [TBL] [Abstract][Full Text] [Related]
10. Outcome of adjuvant therapy in biliary tract cancers. McNamara MG; Walter T; Horgan AM; Amir E; Cleary S; McKeever EL; Min T; Wallace E; Hedley D; Krzyzanowska M; Moore M; Gallinger S; Greig P; Serra S; Dawson LA; Knox JJ Am J Clin Oncol; 2015 Aug; 38(4):382-7. PubMed ID: 24572429 [TBL] [Abstract][Full Text] [Related]
11. [The possibility of local control of cancer by neoadjuvant chemoradiation therapy with gemcitabine and surgical resection for advanced cholangiocarcinoma]. Nakagawa K; Katayose Y; Rikiyama T; Okaue A; Unno M Gan To Kagaku Ryoho; 2009 Nov; 36(12):2009-11. PubMed ID: 20037307 [TBL] [Abstract][Full Text] [Related]
12. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. Glazer ES; Liu P; Abdalla EK; Vauthey JN; Curley SA J Gastrointest Surg; 2012 Sep; 16(9):1666-71. PubMed ID: 22777053 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer. Ma KW; Cheung TT; She WH; Chok KSH; Chan ACY; Dai WC; Chiu WH; Lo CM World J Surg; 2018 Mar; 42(3):823-834. PubMed ID: 28905105 [TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731 [TBL] [Abstract][Full Text] [Related]
15. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Kobayashi S; Nagano H; Tomokuni A; Gotoh K; Sakai D; Hatano E; Seo S; Terajima H; Uchida Y; Ajiki T; Satake H; Kamei K; Tohyama T; Hirose T; Ikai I; Morita S; Ioka T; Ann Surg; 2019 Aug; 270(2):230-237. PubMed ID: 30339627 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). Fujiwara Y; Kobayashi S; Nagano H; Kanai M; Hatano E; Toyoda M; Ajiki T; Takashima Y; Yoshimura K; Hamada A; Minami H; Ioka T PLoS One; 2015; 10(12):e0143072. PubMed ID: 26633034 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors. Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151 [TBL] [Abstract][Full Text] [Related]
18. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Polistina FA; Guglielmi R; Baiocchi C; Francescon P; Scalchi P; Febbraro A; Costantin G; Ambrosino G Radiother Oncol; 2011 May; 99(2):120-3. PubMed ID: 21621289 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713 [TBL] [Abstract][Full Text] [Related]